36氪 was informed that the high-end skin care brand “Suhua” has recently completed a strategic financing of tens of millions of yuan. The investor is the listed company Ruoyuchen, and Inspur Capital served as the exclusive financial advisor for this round of financing.
Previously, Suhua has completed tens of millions of RMB angel round financing, exclusively invested by a well-known industrial capital. This round of financing will be mainly used for self-developed core raw material production, brand building, team building and other aspects.
Founded in 2021, Suhua is a mid-to-high-end skin care brand based on high-end synthetic biotechnology and using humanized collagen as the core ingredient. Guangzhou Meishen Biotechnology Co., Ltd. is its parent company. It is an innovative biotechnology enterprise based on synthetic biology engineering platform, integrating its own raw material research and development, core formulation development, brand management and terminal sales.
Founder Li Jia told 36氪 that the human homologous C3 recombinant collagen independently developed by Suhua has taken the lead in realizing the penetration test of the human body. The human body permeability experiment adopts the world’s leading photoacoustic technology. The technology and experiment were jointly completed by the team of Chinese scientist Dr. Liu Chengbo and the team of Professor Zhang Guangxian.
Photoacoustic Imaging Penetration Experiment Diagram
According to Li Jia, in this experiment on the permeability of human skin with recombinant collagen, the traditional animal experiment of pigskin and cowhide was abandoned. The team led by Chinese scientist Dr. Liu Chengbo applied the human homologous recombinant collagen C3 solution to the skin of the subjects. , and realizes the whole process of non-invasive and visualized dermal penetration through photoacoustic/fluorescence confocal microscopy imaging technology. “This is different from traditional animal experiments, cell experiments, and 3D skin experiments. It is a scientific invention of international leading significance. This application breakthrough has huge market potential in the field of skin care product testing.”
Recombinant humanized collagen is a functional protein that is 100% identical to the human DNA sequence and structure produced by synthetic biology. Compared with ordinary collagen, it will not cause rejection when applied to the human body, and has no hidden virus. Stable, water-soluble, high biological activity and other characteristics. Based on these advantages, recombinant humanized collagen has been used as a skin care ingredient in the past two years.
At present, the C3 recombinant collagen independently developed by Suhua has been applied to its entire line of skin care products. It is reported that Suhua’s main product is the “C3 Baby Collagen” anti-aging series, which now has six categories of essence, water, milk, cream and facial cleanser, with a total of 7 SKUs. By the end of this year, it is expected to achieve 19 SKUs, including second-class medical devices and cosmetics.
Traceability products, photo provided by respondents
In the second half of 2021, Suhua Tmall flagship store will open, and within 5 months, it will become the fastest growing brand in this segment. Li Jia told 36 Krypton that Suhua products will undergo rigorous and scientific third-party human efficacy testing before they go online. At present, the unit price of the product remains above 400 yuan, the repurchase rate is 25%, and the gross profit margin is 87%.
In July this year, Suhua joined the “Tiangong Kaiwu” bio-economy industry acceleration platform, a total of 16 companies including Azurite Microorganisms, Country Garden Ventures, Fengrui Capital, Hillhouse Ventures, Lightspeed China, L’Oreal, and Meishen Bio-Germany. Co-sponsored by the founding units, among them, the platform’s founding units only have two seats in the beauty field, one is L’Oreal, a leading beauty company in the world’s top 500, and the other is Meishen Bio.
The founding team of Suhua includes the former CEO of a beauty company on the New Third Board, a professor from a top medical college in China, and a former vice president of a listed medical device company.
media coverage
36Kr investment community start-up state
This article is reprinted from: https://readhub.cn/topic/8jWqUzSdx24
This site is for inclusion only, and the copyright belongs to the original author.